<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433755</url>
  </required_header>
  <id_info>
    <org_study_id>20150172</org_study_id>
    <nct_id>NCT03433755</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to learn more about evolocumab in Chinese people with primary&#xD;
      hypercholesterolemia or mixed dyslipidemia. This study will see if evolocumab will reduce low&#xD;
      density lipoprotein cholesterol (LDL-C) in Chinese people who are also taking a certain type&#xD;
      of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any&#xD;
      side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of&#xD;
      evolocumab in Chinese participants with hypercholesterolemia and mixed dyslipidemia.&#xD;
      Participants who have signed the informed consent form (ICF) will have fasting lipids&#xD;
      measured and all inclusion and exclusion criteria assessed. All eligible participants must be&#xD;
      taking a maximum appropriate dose of an approved statin, not requiring up titration.&#xD;
      Participants should maintain their current diet and exercise regimen.&#xD;
&#xD;
      Treatment and follow-up period will be 12 weeks with an additional phone call or other&#xD;
      participant contact at week 14 for those receiving investigational product every 2 weeks&#xD;
      (Q2W). The end of study (EOS) for participants on once monthly (QM) investigational product&#xD;
      is at the week 12 visit, which must be at least 30 days post last dose of investigational&#xD;
      product.&#xD;
&#xD;
      Evolocumab or placebo will be administered by self-injection under the skin at the study site&#xD;
      or in an appropriate non-clinic setting (e.g., at home) by spring based prefilled auto&#xD;
      injector/pen (AI/Pen). Participants must tolerate an injection of placebo with a prefilled&#xD;
      auto injector/pen device to be used during the study prior to randomization.&#xD;
&#xD;
      Participants will be randomly added to 1 of 4 groups using a 2:2:1:1 ratio:&#xD;
&#xD;
      evolocumab 140 mg Q2W (86 participants total) evolocumab 420 mg QM (86 participants total)&#xD;
      placebo Q2W (44 participants total) placebo QM (43 participants total). The dose frequencies&#xD;
      of Q2W and QM will not be blinded but the identity of investigational product evolocumab or&#xD;
      placebo will be blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Prematurely Discontinued Amgen decision&#xD;
  </why_stopped>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Actual">May 9, 2020</completion_date>
  <primary_completion_date type="Actual">April 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be screened for this study and if found eligible as described by the study protocol may be randomized into 1 of 4 groups. Randomized means that you are put into a group by chance. It is like drawing numbers out of a hat. Randomization will be done using a 2:2:1:1 ratio. This means for every 6 participants randomized:&#xD;
2 participants will be randomized to evolocumab 140 mg every 2 weeks&#xD;
2 participants will be randomized to evolocumab 420 mg once a month&#xD;
1 participant will be randomized to placebo every 2 weeks&#xD;
1 participant will be randomized to placebo once a month.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The dose frequencies of Q2W and QM will not be blinded but the identity of investigational product (evolocumab or matching SC placebo) will be blinded. In order to protect the blinding of the double-blind treatment period the following labs will be blinded post-investigational product treatment until unblinding of the clinical database and not reported to sites as noted below:&#xD;
â€¢ Blinded to the Amgen study team and site staff: lipid panel, Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), lipoprotein(a), high-sensitivity C-reactive protein (hs-CRP), and Proprotein convertase subtilisin/kexin type 9 (PCSK9).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C: Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in ApoB at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Target LDL-C &lt; 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12</measure>
    <time_frame>Weeks 10 and 12</time_frame>
    <description>Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Target LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lp(a) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline, Weeks 10 and 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in VLDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">259</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous (SC) Q2W for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC QM for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 420 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab 420 mg SC QM for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evolocumab</intervention_name>
    <description>Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.</description>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 420 mg QM</arm_group_label>
    <other_name>Repatha; AMG 145</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo QM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female â‰¥ 18 years of age at signing of informed consent form&#xD;
&#xD;
          -  On an approved statin, with or without ezetimibe, at optimal stable daily dose(s) for&#xD;
             at least 4 weeks before LDL-C screening and, in the opinion of the investigator, not&#xD;
             requiring uptitration&#xD;
&#xD;
          -  Fasting LDL-C as determined by central laboratory at screening â‰¥ 80 mg/dL&#xD;
&#xD;
          -  Subject meets at least 1 of the following criteria for high/very high cardiovascular&#xD;
             (CV) riskï¼š&#xD;
&#xD;
               -  history of coronary artery disease&#xD;
&#xD;
               -  history of ischemic stroke&#xD;
&#xD;
               -  diagnosis of peripheral artery disease&#xD;
&#xD;
               -  an estimated glomerular filtration rate (eGFR) as determined by central&#xD;
                  laboratory at screening of â‰¥ 30 but &lt; 60 ml/min/1.73m^2&#xD;
&#xD;
               -  diagnosis of diabetes mellitus type 2&#xD;
&#xD;
               -  presence of â‰¥ 3 of the following risk factors: â‰¥ 45 years of age if male; â‰¥ 55&#xD;
                  years of age if female; hypertension; smoking; family history of premature&#xD;
                  cardiovascular disease (CVD; 1st degree of relative: male &lt; 55 yr, female &lt; 65&#xD;
                  yr); high-density lipoprotein (HDL) cholesterol &lt; 40 mg/dL; obesity (body mass&#xD;
                  index â‰¥ 28 kg/m^2)&#xD;
&#xD;
        OR&#xD;
&#xD;
        Subject does not meet high/very high CV risk criteria but fasting LDL-C as determined by&#xD;
        central laboratory at screening â‰¥ 130 mg/dl&#xD;
&#xD;
          -  Fasting triglycerides â‰¤ 400 mg/dL (4.5 mmol/L) by determined by central laboratory at&#xD;
             screening&#xD;
&#xD;
          -  Subject tolerates a screening placebo injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),&#xD;
             coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization&#xD;
&#xD;
          -  Planned coronary or other revascularization within 20 weeks of screening&#xD;
&#xD;
          -  New York Heart Association (NYHA) III or IV heart failure, or last known left&#xD;
             ventricular ejection fraction &lt; 30&#xD;
&#xD;
          -  Uncontrolled serious cardiac arrhythmia defined as recurrent and highly symptomatic&#xD;
             ventricular tachycardia, atrial fibrillation with rapid ventricular response, or&#xD;
             supraventricular tachycardia that are not controlled by medications, in the past 3&#xD;
             months prior to randomization&#xD;
&#xD;
          -  Type 1 diabetes, new-onset (hemoglobin [Hb]A1c â‰¥ 6.5% or fasting plasma glucose (FPG)&#xD;
             â‰¥ 126 mg/dL at screening without known diagnosis) or poorly controlled (HbA1c â‰¥ 8.5%)&#xD;
             type 2 diabetes, as determined by central laboratory at screening&#xD;
&#xD;
          -  Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) &gt; 180 mmHg&#xD;
             or diastolic blood pressure (DBP) &gt; 110 mmHg&#xD;
&#xD;
          -  Subject has taken a cholesterylester transfer protein (CETP) inhibitor in the 12&#xD;
             months prior to randomization&#xD;
&#xD;
          -  Subject has taken in the 6 weeks prior to LDL-C screening: red yeast rice, &gt; 200&#xD;
             mg/day niacin, &gt; 1000 mg/day omega-3 fatty acids (eg, dihydroxyacetone docosahexaenoic&#xD;
             acid and eicosapentaenoic acid), stanols or prescription lipid-regulating drugs (eg,&#xD;
             bile-acid sequestering resins, fibrates and derivatives) or other cholesterol lowering&#xD;
             drugs or lipid-lowering dietary supplements or food additives other than statins and&#xD;
             ezetimibe&#xD;
&#xD;
          -  Treatment 3 months prior to LDL-C screening with any of the following drugs: systemic&#xD;
             cyclosporine, systemic steroids, (intravenous [IV], intramuscular [IM], or by-mouth&#xD;
             [PO]) (Note: hormone replacement therapy is permitted), vitamin A derivatives and&#xD;
             retinol derivatives for the treatment of dermatologic conditions (eg, Accutane) (Note:&#xD;
             vitamin A in a multivitamin preparation is permitted)&#xD;
&#xD;
          -  Uncontrolled hypothyroidism or hyperthyroidism as defined by thyroid stimulating&#xD;
             hormone (TSH) &lt; 1.0 time the lower limit of normal (LLN) or &gt; 1.5 times the upper&#xD;
             limit of normal (ULN), respectively, at screening&#xD;
&#xD;
          -  Severe renal dysfunction, defined as an eGFR &lt; 30 ml/min/1.73m^2 at screening as&#xD;
             estimated by Cockcroft-Gault method&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase&#xD;
             (AST) or alanine aminotransferase (ALT) &gt; 3 times the ULN as determined by central&#xD;
             laboratory analysis at screening&#xD;
&#xD;
          -  Creatinine kinase (CK) &gt; 5 times the ULN at screening&#xD;
&#xD;
          -  Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast&#xD;
             ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years prior&#xD;
             to randomization&#xD;
&#xD;
          -  Subject has previously received evolocumab or any other therapy to inhibit PCSK9&#xD;
&#xD;
          -  Subject has known sensitivity to any of the active substances or their excipients to&#xD;
             be administered during dosing, eg, carboxymethylcellulose&#xD;
&#xD;
          -  Subject likely to not be available to complete all protocol-required study visits or&#xD;
             procedures, and/or to comply with all required study procedures to the best of the&#xD;
             subject and investigator's knowledge.&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition or disease&#xD;
             (with the exception of those outlined above) that, in the opinion of the investigator&#xD;
             or Amgen physician, if consulted, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures or completion.&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study, or less&#xD;
             than 30 days before randomization since ending treatment on another investigational&#xD;
             device or drug study(s) or planning to receive other investigational procedures while&#xD;
             participating in this study&#xD;
&#xD;
          -  Female subject of childbearing potential not willing to use an acceptable method(s) of&#xD;
             effective birth control during treatment with investigational product and for an&#xD;
             additional 15 weeks after the end of treatment with investigational product. Female&#xD;
             subjects of non-childbearing potential who are not required to use contraception&#xD;
             during the study and include those who have had a:&#xD;
&#xD;
               -  hysterectomy&#xD;
&#xD;
               -  bilateral salpingectomy&#xD;
&#xD;
               -  bilateral oophorectomy or&#xD;
&#xD;
               -  who are postmenopausal i. A postmenopausal state is defined as no menses for 12&#xD;
                  months without an alternative medical cause. [A high follicle stimulating hormone&#xD;
                  (FSH) level in the postmenopausal range may be used to confirm a postmenopausal&#xD;
                  state in women not using hormonal contraception or hormonal replacement therapy&#xD;
                  (HRT). However, in the absence of 12 months of amenorrhea, a single FSH&#xD;
                  measurement is insufficient.&#xD;
&#xD;
        ii. Females on HRT and whose menopausal status is in doubt will be required to use one of&#xD;
        the non-hormonal highly effective contraception methods if they wish to continue their HRT&#xD;
        during the study. Otherwise, they must discontinue HRT to allow confirmation of&#xD;
        postmenopausal status before study enrollment.&#xD;
&#xD;
        Acceptable methods of effective birth control include:&#xD;
&#xD;
          -  sexual abstinence (defined as refraining from heterosexual intercourse during the&#xD;
             entire period of risk associated with the study treatments; the reliability of sexual&#xD;
             abstinence must be evaluated in relation to the duration of the trial and the&#xD;
             preferred and usual lifestyle of the subject. [Periodic abstinence (eg., calendar,&#xD;
             ovulation, symptothermal, postovulation methods), declaration of abstinence for the&#xD;
             duration of a study, and withdrawal are not acceptable methods of contraception])&#xD;
&#xD;
          -  bilateral tubal ligation/occlusion&#xD;
&#xD;
          -  vasectomized partner (provided that partner is the sole sexual partner of the female&#xD;
             subject of childbearing potential and that the vasectomized partner has received&#xD;
             medical assessment of the surgical success)&#xD;
&#xD;
          -  use of hormonal birth control methods (oral, intravaginal (eg. vaginal ring(s),&#xD;
             transdermal, injectable, or implantable)&#xD;
&#xD;
          -  intrauterine devices (IUDs)&#xD;
&#xD;
          -  intrauterine hormonal releasing system (IUS)&#xD;
&#xD;
          -  2 barrier methods (each partner must use 1 barrier method) the male uses a condom and&#xD;
             the female must choose either a diaphragm, OR cervical cap, OR contraceptive sponge&#xD;
             with spermicide. If spermicide is not commercially available in the country or region,&#xD;
             the 2 barrier method without spermicide is acceptable. (A female condom is not an&#xD;
             option due to the risk of tearing when both partners use a condom.)&#xD;
&#xD;
               -  Female subject is pregnant or breast feeding (nursing), planning to become&#xD;
                  pregnant or planning to breastfeed (nurse) during treatment with investigational&#xD;
                  product and/or within 15 weeks after the end of treatment with investigational&#xD;
                  product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Peoples Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou First PeoplesÃ‚ Ã‚ Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Red Cross Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510220</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Nanning Peoples Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Puai Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Peoples Hospital</name>
      <address>
        <city>Huhehaote</city>
        <state>Inner Mongolia</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzhou Kowloon Hospital</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Peoples Hospital of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Yangpu District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi An Jiao Tong University</name>
      <address>
        <city>XI An</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Fourth Centre Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300140</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Linhai</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <results_first_submitted>July 26, 2021</results_first_submitted>
  <results_first_submitted_qc>July 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <disposition_first_submitted>March 1, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>March 1, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 3, 2021</disposition_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Evolocumab</keyword>
  <keyword>Repatha</keyword>
  <keyword>Statin</keyword>
  <keyword>Chinese</keyword>
  <keyword>China</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Mixed Dyslipidemia</keyword>
  <keyword>High Cholesterol</keyword>
  <keyword>Lowering cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03433755/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03433755/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 31 research centers in China from 09 May 2019 to 20 January 2020.</recruitment_details>
      <pre_assignment_details>Participants were randomized 2:2:1:1 into the following treatment arms: evolocumab140 mg subcutaneously (SC) every 2 weeks (Q2W); evolocumab 420 mg SC once monthly (QM); placebo SC Q2W, or placebo SC QM. Randomization was stratified by entry cardiovascular (CV) risk (high/very high vs. not high/very high). Due to Human Genetic Resource Administration office of China (HGRAC) regulations/restrictions, 17 participants were not included in any analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Q2W</title>
          <description>Placebo subcutaneous (SC) Q2W for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo QM</title>
          <description>Placebo SC QM for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Evolocumab 420 mg QM</title>
          <description>Evolocumab 420 mg SC QM for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set: All participants who were randomized and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Q2W</title>
          <description>Placebo SC Q2W for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo QM</title>
          <description>Placebo SC QM for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Evolocumab 420 mg QM</title>
          <description>Evolocumab 420 mg SC QM for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="79"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="9.8"/>
                    <measurement group_id="B2" value="59.4" spread="10.9"/>
                    <measurement group_id="B3" value="61.2" spread="10.6"/>
                    <measurement group_id="B4" value="60.9" spread="9.8"/>
                    <measurement group_id="B5" value="60.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Cardiovascular (CV) Risk</title>
          <description>See eligibility criteria for the definition of high/very high cardiovascular (CV) risk. Participants not meeting high/very high CV risk criteria had fasting LDL-C as determined by central laboratory at screening â‰¥ 130 mg/dl.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High/Very High CV Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not High/Very High CV Risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein Cholesterol (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120.9" spread="42.2"/>
                    <measurement group_id="B2" value="117.1" spread="28.2"/>
                    <measurement group_id="B3" value="113.7" spread="37.7"/>
                    <measurement group_id="B4" value="115.5" spread="30.1"/>
                    <measurement group_id="B5" value="116.1" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="3.72"/>
                    <measurement group_id="O2" value="-68.86" spread="3.27"/>
                    <measurement group_id="O3" value="-0.36" spread="3.78"/>
                    <measurement group_id="O4" value="-70.10" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-70.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.98</ci_lower_limit>
            <ci_upper_limit>-63.48</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-69.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.51</ci_lower_limit>
            <ci_upper_limit>-62.97</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="4.18"/>
                    <measurement group_id="O2" value="-68.39" spread="3.55"/>
                    <measurement group_id="O3" value="2.72" spread="4.25"/>
                    <measurement group_id="O4" value="-63.09" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-70.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.47</ci_lower_limit>
            <ci_upper_limit>-62.27</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-65.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.97</ci_lower_limit>
            <ci_upper_limit>-57.66</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C: Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C: Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="5.4"/>
                    <measurement group_id="O2" value="-77.1" spread="4.8"/>
                    <measurement group_id="O3" value="-5.8" spread="5.8"/>
                    <measurement group_id="O4" value="-83.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-76.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.6</ci_lower_limit>
            <ci_upper_limit>-66.4</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-77.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.7</ci_lower_limit>
            <ci_upper_limit>-66.7</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="5.8"/>
                    <measurement group_id="O2" value="-76.7" spread="5.1"/>
                    <measurement group_id="O3" value="-2.1" spread="6.1"/>
                    <measurement group_id="O4" value="-75.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-75.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.1</ci_lower_limit>
            <ci_upper_limit>-64.7</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-73.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.1</ci_lower_limit>
            <ci_upper_limit>-61.8</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="3.52"/>
                    <measurement group_id="O2" value="-58.84" spread="3.10"/>
                    <measurement group_id="O3" value="-0.06" spread="3.30"/>
                    <measurement group_id="O4" value="-62.20" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-61.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.04</ci_lower_limit>
            <ci_upper_limit>-54.37</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-62.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.97</ci_lower_limit>
            <ci_upper_limit>-56.32</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="3.85"/>
                    <measurement group_id="O2" value="-57.59" spread="3.30"/>
                    <measurement group_id="O3" value="1.78" spread="3.70"/>
                    <measurement group_id="O4" value="-54.86" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-61.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.25</ci_lower_limit>
            <ci_upper_limit>-53.65</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-56.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.66</ci_lower_limit>
            <ci_upper_limit>-49.63</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="3.17"/>
                    <measurement group_id="O2" value="-54.45" spread="2.79"/>
                    <measurement group_id="O3" value="0.07" spread="3.00"/>
                    <measurement group_id="O4" value="-56.93" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>-56.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.44</ci_lower_limit>
            <ci_upper_limit>-50.07</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>-57.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.35</ci_lower_limit>
            <ci_upper_limit>-51.65</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in ApoB at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in ApoB at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="3.55"/>
                    <measurement group_id="O2" value="-53.16" spread="3.03"/>
                    <measurement group_id="O3" value="1.20" spread="3.51"/>
                    <measurement group_id="O4" value="-50.01" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-55.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.98</ci_lower_limit>
            <ci_upper_limit>-48.41</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-51.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.06</ci_lower_limit>
            <ci_upper_limit>-44.37</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="2.74"/>
                    <measurement group_id="O2" value="-41.42" spread="2.42"/>
                    <measurement group_id="O3" value="-0.09" spread="2.68"/>
                    <measurement group_id="O4" value="-44.39" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-42.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.06</ci_lower_limit>
            <ci_upper_limit>-37.41</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-44.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.02</ci_lower_limit>
            <ci_upper_limit>-39.58</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo 420 mg SC QM</title>
            <description>Placebo 420 mg SC QM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="2.99"/>
                    <measurement group_id="O2" value="-40.36" spread="2.57"/>
                    <measurement group_id="O3" value="1.17" spread="2.96"/>
                    <measurement group_id="O4" value="-39.25" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-43.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.09</ci_lower_limit>
            <ci_upper_limit>-37.00</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-40.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.98</ci_lower_limit>
            <ci_upper_limit>-34.87</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Target LDL-C &lt; 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12</title>
        <description>Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.</description>
        <time_frame>Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Target LDL-C &lt; 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12</title>
          <description>Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.5" upper_limit="13.8"/>
                    <measurement group_id="O2" value="89.9" lower_limit="80.5" upper_limit="95.0"/>
                    <measurement group_id="O3" value="5.7" lower_limit="1.6" upper_limit="18.6"/>
                    <measurement group_id="O4" value="97.2" lower_limit="90.3" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on Cochran Mantel Haenszel (CMH) test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>87.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.6</ci_lower_limit>
            <ci_upper_limit>92.8</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>91.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.9</ci_lower_limit>
            <ci_upper_limit>96.1</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Target LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Target LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12</title>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.2"/>
                    <measurement group_id="O2" value="90.6" lower_limit="81.0" upper_limit="95.6"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.7" upper_limit="18.3"/>
                    <measurement group_id="O4" value="89.4" lower_limit="79.7" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>90.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.6</ci_lower_limit>
            <ci_upper_limit>95.6</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>85.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.2</ci_lower_limit>
            <ci_upper_limit>91.9</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12</title>
        <description>Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12</title>
          <description>Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="87.0" lower_limit="77.0" upper_limit="93.0"/>
                    <measurement group_id="O3" value="5.7" lower_limit="1.6" upper_limit="18.6"/>
                    <measurement group_id="O4" value="94.4" lower_limit="86.4" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>87.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.3</ci_lower_limit>
            <ci_upper_limit>93.0</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>88.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.5</ci_lower_limit>
            <ci_upper_limit>94.0</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12</title>
        <description>LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12</title>
          <description>LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with observed data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.2"/>
                    <measurement group_id="O2" value="82.8" lower_limit="71.8" upper_limit="90.1"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.7" upper_limit="18.3"/>
                    <measurement group_id="O4" value="86.4" lower_limit="76.1" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>82.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.8</ci_lower_limit>
            <ci_upper_limit>90.1</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on CMH test adjusted by the stratification factor.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>82.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.8</ci_lower_limit>
            <ci_upper_limit>89.7</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="4.97"/>
                    <measurement group_id="O2" value="-43.49" spread="4.46"/>
                    <measurement group_id="O3" value="11.27" spread="4.37"/>
                    <measurement group_id="O4" value="-29.16" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-48.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.78</ci_lower_limit>
            <ci_upper_limit>-39.11</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-40.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.62</ci_lower_limit>
            <ci_upper_limit>-32.24</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lp(a) at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lp(a) at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="5.21"/>
                    <measurement group_id="O2" value="-42.83" spread="4.60"/>
                    <measurement group_id="O3" value="14.53" spread="5.64"/>
                    <measurement group_id="O4" value="-23.73" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-44.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.76</ci_lower_limit>
            <ci_upper_limit>-34.65</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-38.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.94</ci_lower_limit>
            <ci_upper_limit>-26.59</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="4.77"/>
                    <measurement group_id="O2" value="-9.86" spread="4.19"/>
                    <measurement group_id="O3" value="3.03" spread="4.85"/>
                    <measurement group_id="O4" value="-16.64" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-15.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.44</ci_lower_limit>
            <ci_upper_limit>-5.75</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-19.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.30</ci_lower_limit>
            <ci_upper_limit>-11.05</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.01" spread="5.63"/>
                    <measurement group_id="O2" value="-7.55" spread="4.73"/>
                    <measurement group_id="O3" value="0.69" spread="5.56"/>
                    <measurement group_id="O4" value="-11.66" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-17.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.42</ci_lower_limit>
            <ci_upper_limit>-5.69</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-12.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.04</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="2.65"/>
                    <measurement group_id="O2" value="9.45" spread="2.35"/>
                    <measurement group_id="O3" value="1.86" spread="2.60"/>
                    <measurement group_id="O4" value="8.66" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>8.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.35</ci_lower_limit>
            <ci_upper_limit>13.52</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>6.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>11.50</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="2.88"/>
                    <measurement group_id="O2" value="9.89" spread="2.49"/>
                    <measurement group_id="O3" value="0.95" spread="2.97"/>
                    <measurement group_id="O4" value="7.12" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>7.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.18</ci_lower_limit>
            <ci_upper_limit>13.71</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>6.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>11.92</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline, Weeks 10 and 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="5.32"/>
                    <measurement group_id="O2" value="-15.88" spread="4.73"/>
                    <measurement group_id="O3" value="4.95" spread="4.97"/>
                    <measurement group_id="O4" value="-22.87" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-22.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.12</ci_lower_limit>
            <ci_upper_limit>-12.81</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-27.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.60</ci_lower_limit>
            <ci_upper_limit>-19.02</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in VLDL-C at Week 12</title>
        <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Placebo SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo QM</title>
            <description>Placebo SC QM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 420 mg QM</title>
            <description>Evolocumab 420 mg SC QM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in VLDL-C at Week 12</title>
          <description>Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</description>
          <population>Full Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants with baseline and post-baseline assessments.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.23" spread="6.12"/>
                    <measurement group_id="O2" value="-10.55" spread="5.22"/>
                    <measurement group_id="O3" value="1.72" spread="5.57"/>
                    <measurement group_id="O4" value="-14.02" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-21.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.31</ci_lower_limit>
            <ci_upper_limit>-9.25</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>Includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>-15.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.31</ci_lower_limit>
            <ci_upper_limit>-5.18</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mortality: from randomization to end of study (EOS) date; median (min, max) duration was 3.22 (0.99, 4.01) months. AEs: from first dose up to last dose + 30 days or EOS date, whichever was earlier; median (min, max) duration was 2.86 (1.02, 3.88) months.</time_frame>
      <desc>Mortality is reported for randomized participants. Serious and other AEs are reported for randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q2W</title>
          <description>Placebo SC Q2W for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo QM</title>
          <description>Placebo SC Q2W for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Evolocumab 140 mg SC Q2W for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Evolocumab 420 mg QM</title>
          <description>Evolocumab 420 mg SC QM for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal clotting factor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Left atrial enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Congestive hepatopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bacterial test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Carotid intima-media thickness increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>pH urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypovitaminosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Prostatic calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vascular wall hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

